![Gary Jennings](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Gary Jennings is the founder of JADO Technologies GmbH, which was founded in 2001.
He held the title of Chief Scientific Officer from 2001 to 2014.
Dr. Jennings also held former positions at DeveloGen AG and HepaVec AG as Head-Cell Engineering, and at Ribonetics GmbH as Principal.
Dr. Jennings received a doctorate degree from The University of York.
Former positions of Gary Jennings
Companies | Position | End |
---|---|---|
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Founder | 17/04/2014 |
Ribonetics GmbH
![]() Ribonetics GmbH BiotechnologyHealth Technology Part of Baxter International, Inc., Ribonetics GmbH is a German company that develops RILON technology, a therapeutic treatment. The company is located in Germany. Ribonetics was acquired by Nexell Therapeutics, Inc. on May 23, 1996 for $1.50 million. | Corporate Officer/Principal | - |
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - |
HepaVec AG
![]() HepaVec AG Pharmaceuticals: MajorHealth Technology Part of Evotec SE, HepaVec AG is a German pharmaceutical company that develops pharmaceutical products. The company is based in Berlin, Germany. HepaVec was acquired by DeveloGen AG on May 01, 2000 for $46.57 million. | Corporate Officer/Principal | - |
Training of Gary Jennings
The University of York | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Retail Trade |
HepaVec AG
![]() HepaVec AG Pharmaceuticals: MajorHealth Technology Part of Evotec SE, HepaVec AG is a German pharmaceutical company that develops pharmaceutical products. The company is based in Berlin, Germany. HepaVec was acquired by DeveloGen AG on May 01, 2000 for $46.57 million. | Health Technology |
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Ribonetics GmbH
![]() Ribonetics GmbH BiotechnologyHealth Technology Part of Baxter International, Inc., Ribonetics GmbH is a German company that develops RILON technology, a therapeutic treatment. The company is located in Germany. Ribonetics was acquired by Nexell Therapeutics, Inc. on May 23, 1996 for $1.50 million. | Health Technology |
- Stock Market
- Insiders
- Gary Jennings